Skip to main content

View full-text article in PMC

. 2022 Jun 15;11(3):1235–1252. doi: 10.1007/s40120-022-00370-8

Table 3.

Adverse events for atogepant versus placebo

Outcome	Number of studies [References]	Number of pooled events/participants		I²	Risk ratio (95% CI)	p value
Outcome	Number of studies [References]	Atogepant	Placebo	I²	Risk ratio (95% CI)	p value
Any AE	2 [23, 24]	643/1142	218/408	85.6%	1.07 (0.81–1.41)^a	0.630
Any SAE	2 [23, 24]	7/1142	4/408	0.0%	0.66 (0.20–2.20)	0.496
Discontinuation due to AEs	2 [23, 24]	40/1142	11/408	0.0%	1.32 (0.69–2.55)	0.402
Constipation	2 [23, 24]	70/1142	5/408	74.4%	5.03 (0.56–44.90)^a	0.148
Nasopharyngitis	2 [23, 24]	48/1142	12/408	71.9%	1.46 (0.79–2.70)	0.230
Nausea	2 [23, 24]	75/1142	13/408	0.0%	2.13 (1.19–3.80)	0.010
Upper respiratory tract infection	2 [23, 24]	61/1142	25/408	0.0%	0.89 (0.57–1.40)	0.616
Urinary tract infection	2 [23, 24]	39/1142	12/408	18.0%	1.16 (0.62–2.19)	0.639

AE adverse event, CI confidence interval, SAE serious adverse event

^aRisk ratio from random-effect model